{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:36:51Z","timestamp":1782509811626,"version":"3.54.5"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institutes of Health T-32","award":["5T32CA093245"],"award-info":[{"award-number":["5T32CA093245"]}]},{"name":"National Institutes of Health T-32","award":["5T32HL069749"],"award-info":[{"award-number":["5T32HL069749"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["CA160891"],"award-info":[{"award-number":["CA160891"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is no standard of care with respect to the use of neoadjuvant chemotherapy (NAC) in resectable malignant pleural mesothelioma (MPM). We performed an intention-to-treat analysis with data from a single institution and the National Cancer Database (NCDB) to identify whether the use of NAC impacts survival in resectable MPM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with MPM who had surgery with curative intent at Duke University from 1995 to 2017 were selected, and the 2004\u20132015 NCDB was used to identify MPM patients with clinical stage I\u2013IIIB who underwent definitive surgery. For both cohorts, patients were stratified by receipt of NAC. Primary outcomes were overall survival and postresection survival (RS), which were estimated using Kaplan-Meier and multivariable Cox proportional hazards models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 257 patients met inclusion criteria in the Duke cohort. Compared with immediate resection (IR), NAC was associated with similar overall survival but an increased risk for postresection mortality in both unmatched (adjusted hazard ratio [HR]\u2009=\u20091.85, 95% confidence interval [CI]\u2009=\u20091.21 to 2.83) and propensity-matched (HR = 1.62, 95% CI = 1.03 to 2.55) cohorts. A total of 1949 NCDB patients were included: 1597 (81.9%) IR and 352 (18.1%) NAC. RS was worse for patients undergoing NAC in both unmatched (HR = 1.85, 95% CI = 1.21 to 2.83) and propensity-matched (HR = 1.29, 95% CI = 1.06 to 1.57) analyses compared with patients receiving IR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this intention-to-treat study, NAC was associated with worse RS compared with IR in patients with MPM. The risks and benefits of induction therapy should be weighed before offering it to patients with resectable MPM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djaa002","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T20:10:17Z","timestamp":1579723817000},"page":"1118-1127","source":"Crossref","is-referenced-by-count":18,"title":["The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma\u2014An Institutional and National Analysis"],"prefix":"10.1093","volume":"112","author":[{"given":"Soraya L","family":"Voigt","sequence":"first","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Raman","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver K","family":"Jawitz","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-3600","authenticated-orcid":false,"given":"Muath","family":"Bishawi","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fu Jeffrey","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty C","family":"Tong","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Harpole","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"2","key":"2021020301055704200_djaa002-B1","first-page":"376","article-title":"Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy\/decortication or extended pleurectomy?","volume":"20","author":"Hountis","year":"2015","journal-title":"J Buon"},{"issue":"2","key":"2021020301055704200_djaa002-B2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"issue":"4","key":"2021020301055704200_djaa002-B3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtcvs.2013.01.039","article-title":"The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass","volume":"145","author":"Rusch","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"14","key":"2021020301055704200_djaa002-B4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"2021020301055704200_djaa002-B5","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021020301055704200_djaa002-B6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021020301055704200_djaa002-B7","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.lungcan.2005.03.014","article-title":"Neoadjuvant chemotherapy in malignant pleural mesothelioma","volume":"49 (suppl 1","author":"Stahel","year":"2005","journal-title":"Lung Cancer"},{"key":"2021020301055704200_djaa002-B8","first-page":"13(6):579\u2013584","article-title":"The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma","author":"Shohdy","year":"2019","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"2021020301055704200_djaa002-B9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.lungcan.2013.04.019","article-title":"Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections","volume":"81","author":"Bolukbas","year":"2013","journal-title":"Lung Cancer"},{"key":"2021020301055704200_djaa002-B10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2017.07.010","article-title":"Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: predictive factors and outcomes","volume":"111","author":"Lau","year":"2017","journal-title":"Lung Cancer"},{"key":"2021020301055704200_djaa002-B11","year":"2018"},{"issue":"5","key":"2021020301055704200_djaa002-B12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2021020301055704200_djaa002-B13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-13-22","article-title":"Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma","volume":"13","author":"Federico","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"2021020301055704200_djaa002-B14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.semtcvs.2015.02.007","article-title":"Surgical management of malignant pleural mesothelioma: an update of clinical evidence","volume":"27","author":"Cao","year":"2015","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"8","key":"2021020301055704200_djaa002-B15","first-page":"1","article-title":"Nonparametric preprocessing for parametric causal inference","volume":"42","author":"Stuart","year":"2011","journal-title":"J Stat Soft"},{"issue":"3","key":"2021020301055704200_djaa002-B16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"2021020301055704200_djaa002-B17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021020301055704200_djaa002-B18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2016.07.023","article-title":"How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?","volume":"100","author":"Sharkey","year":"2016","journal-title":"Lung Cancer"},{"issue":"2","key":"2021020301055704200_djaa002-B19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","article-title":"Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection","volume":"157","author":"Verma","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"2021020301055704200_djaa002-B20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.21037\/tlcr.2018.05.07","article-title":"A randomized phase II study of pleurectomy\/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205)","volume":"7","author":"Raskin","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"2021020301055704200_djaa002-B21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-015-0925-1","article-title":"Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2021020301055704200_djaa002-B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.semtcvs.2014.08.003","article-title":"Novel induction therapies for pleural mesothelioma","volume":"26","author":"Donahoe","year":"2014","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"1","key":"2021020301055704200_djaa002-B23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2012.03.001","article-title":"An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma","volume":"39","author":"Pasello","year":"2013","journal-title":"Cancer Treat Rev"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaa002\/32984723\/djaa002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/11\/1118\/34333286\/djaa002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/11\/1118\/34333286\/djaa002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T18:17:03Z","timestamp":1612549023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/112\/11\/1118\/5721361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,2,3]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaa002","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,2,3]]}}}